Market revenue in 2023 | USD 128.6 million |
Market revenue in 2030 | USD 300.3 million |
Growth rate | 12.9% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Illumina Inc, Qiagen NV, Abcam PLC, Takara Bio Inc, Revvity Inc, Maravai LifeSciences Holdings Inc Ordinary Shares - Class A, HTG Molecular Diagnostics Inc, Meridian Bioscience, New England Biolabs, Norgen Biotek, System Biosciences, Amoy Diagnostics, EntroGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mirna sequencing and assay market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 80.48% in 2023. Horizon Databook has segmented the U.S. mirna sequencing and assay market based on product, services covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in research and development spending by major private players to develop innovative & advanced products in the U.S. miRNA sequencing and assay market is expected to drive significant growth in the country. For instance, during FY 2020, Illumina, Inc. spent USD 682 million on research & development to develop new sequencing technology and upgrade the existing technology.
In addition, prominent players are adopting collaboration and distribution strategies to expand their geographic presence. For instance, in June 2020, HTG Molecular Diagnostics, Inc. signed three new European distributor agreements with BioNordika (Denmark), Explorea (Czech Republic), and ELTA 90 (Bulgaria) to promote HTG products & services in Nordic and Eastern European countries.
Furthermore, players also adopting a new product launch strategy to expand their product portfolios and strengthen their market position. For instance, in August 2018, HTG Molecular Diagnostics, Inc. launched HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay (WTA).
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. mirna sequencing and assay market , including forecasts for subscribers. This country databook contains high-level insights into U.S. mirna sequencing and assay market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account